Loading...
 

Background

What is ROC?

The Resuscitation Outcomes Consortium (ROC) was created to conduct clinical research in the areas of cardiopulmonary resuscitation and traumatic injury. ROC consists of 10 Regional Clinical Centers (RCCs), one satellite site and a Data and Coordinating Center (DCC) that will provide the necessary infrastructure to conduct multiple collaborative trials to aid rapid translation of promising scientific and clinical advances to improve resuscitation outcomes. Trials may evaluate existing or new therapies (such as pharmacologic immune modulators) as well as clinical management strategies (such as new resuscitative fluids, novel hemorrhage control strategies, the use of cerebral protection and neurologic preservation, metabolically directed therapies, and alternative methods of delivering CPR or defibrillation).

ROC Report:

June 1, 2013 - Resuscitation Outcomes Consortium (ROC) progress report (2003-2013) and promise for the future

Who are the Sponsors?

ROC has been renewed until 2015 with direct study commitment of the sponsors is for 6 year funding of approximately $10 million per year.

Who will conduct the research?

The ROC consists of EMS systems and hospitals in the cities or regions listed below.

Regional Clinical Centers

Dallas/Fort Worth Center for Resuscitation Research
The Milwaukee Resuscitation Research Center
Ottawa Ontario RCC
British Columbia RCC
Pittsburgh Resuscitation Network
Oregon Health & Sciences University - Portland Resuscitation Outcomes Consortium
Seattle-King County Center for Resuscitation Research at the University of Washington
Alabama Resuscitation Center
Toronto Regional RESusCitation RESearCh oUt of hospital NETwork
UCSD/San Diego Resuscitation Research Center

Satellite Centers

Memphis Resuscitation Research Center Tim Fabian, MD, Principal Investigator
San Francisco Clinical Center Mitchell Cohen, MD, Principal Investigator
Cincinnati Clinical Center Peter Muskat, MD, Principal Investigator
Houston Clinical Center Bryan Cotton, MD, Principal Investigator
Houston Clinical Coordinating Center Barbara Tilley, PhD, Principal Investigator
Houston Data Coordinating Center John Holcomb, MD, Principal Investigator
Toronto,Sunnybrook Clinical Center Sandro Rizoli, MD, Principal Investigator
Baltimore Clinical Center Thomas Scalea, MD, Principal Investigator
Tucson Clinical Center Terence O'Keeffe, MD, Principal Investigator
Los Angeles Clinical Center Kenji Inaba, Principal Investigator
St. Paul Regions Ralph Frascone, MD, Principal Investigator
Mayo Clinic Rochester Martin Zielinski, MD, Principal Investigator
Minneapolis/Hennepin County Paul Nystrum, MD, Principal Investigator

The Study Chair is Myron L. Weisfeldt, MD, Chair of Medicine at Johns Hopkins; the co-chair for cardiac arrest is Joseph Ornato, MD, Head of the Emergency Medicine Department at the Medical College of Virginia; and the co-chair for trauma is David Hoyt, MD, Executive Director, American College of Surgeons, Chicago, IL. The Clinical and Data Coordinating Center is located at the University of Washington, Seattle, WA under the direction of Susanne May, PhD, Gerald van Belle, PhD and Graham Nichol, MD. The Ethics Officer is Jeremy Sugarman, MD, MPH, MA, Berman Bioethics Institute, Johns Hopkins University.

What kind of research will potentially be conducted?

Relevant clinical trials conducted by ROC may include, but are not limited to, the following scientific needs and considerations:

  • Evaluation of pharmacologic interventions to address a three-phase (electrical, circulatory, and metabolic) approach to resuscitation from cardiac arrest.
  • Evaluation of optimal strategies of fluid resuscitation including permissive hypotension, timing of initiation of infusion, and use of alternative fluids particularly after traumatic injury.
  • Use of immune modulators in improving clinical outcomes by altering systemic and/or regional inflammatory responses accompanying shock or shock-like states.
  • Evaluation of novel hemorrhage control strategies.
  • Use of cerebral protection and neurologic preservation, with an emphasis on functional outcome.
  • Evaluation of metabolically directed therapies, such as a rapid induction of moderate systemic hypothermia and other novel methods to reduce metabolic demands in the immediate post-arrest/resuscitation interval.
  • Evaluation of alternative CPR approaches including device-assisted CPR including defibrillators.
  • Evaluation of optimal ventilation and oxygen delivery systems and methods for airway protection.